The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2023 | Advantages of bispecific antibodies for lymphoma: mosunetuzumab, epcoritamab & glofitamab
Neha Mehta-Shah, MD, Washington University in St Louis, St Louis, MO, comments on the advent of bispecific antibodies for the treatment of lymphomas, highlighting the advantages of these agents. Dr. Mehta-Shah explains that bispecific antibodies can be used as either continuous or fixed-duration treatment and offer durable responses coupled with a low risk of cytokine release syndrome (CRS). These agents represent a promising option for patients who cannot receive CAR-T therapy or transplant-based therapies. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
